Sulfatides for treatment of autoimmune disorders

Details Sulfatides for treatment of autoimmune disorders Sulfatides for treatment of autoimmune disorders

2006-09-28

2011-10-25

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S017600

Reexamination Certificate

active

08044029

ABSTRACT:
Disclosed herein are methods for the treatment of autoimmune or immune related diseases or disorders. Also disclosed are methods for treating such autoimmune or immune related diseases or disorders with the administration of sulfatides. Also disclosed herein are methods of treating autoimmune or immune related diseases or disorders by administering an amount of a sulfatide to the body of a patient effective to reduce or prevent the symptoms of the autoimmune or immune related disease or disorder.

REFERENCES:
patent: 5486536 (1996-01-01), Ward et al.
patent: 5565433 (1996-10-01), Banville et al.
patent: 5674690 (1997-10-01), Kolodny et al.
patent: 6352831 (2002-03-01), Buschard et al.
patent: 0 717 995 (1996-06-01), None
Definition of symptom, Merriam-Webster Medical Dictionary, http://www2.merriam-webster.com, accessed online on Jul. 15, 2008.
Marbois et al. Biochimica et Biophysica Acta, 2000, 1484, p. 59-70.
Duran et al. Brain, 1999, 122, p. 2297-2307.
Definition of prevent, Oxford English Dictionary, http://dictionary.oed.com/, accessed online on May 27, 2010.
Compostella et al. Tetrahedron, 2002, 58, p. 8703-8708.
Shamshiev et al. J. Exp. Med. 2002, 195(8), p. 1013-1021.
Entry for Autoimmune disorders, PubMed Health, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001819/, accessed online on Jul. 14, 2011.
Gold et al. Molecular Medicine Today, 2000, 6, p. 88-91.
Zou et al. Neuropharmacology, 2002, 42, p. 731-739.
Buschard et al. (2005) Involvement of sulfatide in beta cells and type 1 and type 2 diabetes. Diabetologia 48:1957-1962.
Hsu et al. (1998) Electrospray ionization tandem mass spectrometric analysis of sulfatide. Determination of fragmentation patterns and characterization of molecular species expressed in brain and in pancreatic islets. Biochimica et Biophysica Acta 1392 202-216.
Steinman, Lawrence and Scott S. Zamvil. “Virtues and Pitfalls of EAE for the Development of Therapies for Multiple Sclerosis.” Trends in Immunology. 26.11 (2005): 565-571.
Mix, Eilhard, et al. “Animal Models of Multiple Sclerosis for the Development and Validation of Novel Therapies—Potential and Limitations.” Journal of Neurology. 255 (Supp 6) (2008): 7-14.
Lassmann, Hans. “Chronic Relapsing Experimental Allergic Encephalomyelitis: Its value as an Experimental Model for Multiple Sclerosis.” Journal of Neurology. 229 (1983): 207-220.
Abreu, Sergio L., et al. “Interferon in Experimental Autoimmune Encephalomyelitis: Intraventricular Administration.” Journal of Interferon Research. 6 (1986): 627-632.
Steinman, Lawrence, MD and Scott S. Zamvil. “How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multiple Sclerosis.” American Neurological Association. 60.12 (2006): 12-21.
Jahng, Alex, et al. “Prevention of Autoimmunity by Targeting a Distinct, Noninvariant CD1d-reactive T Cell Population Reactive to Sulfatide.” Journal of Experimental Medicine. 199.7 (2004): 947-957.
Halder, Ramesh C., et al. “Type II NKT Cell-Mediated Anergy Induction in Type I NKT Cells Prevents Inflammatory Liver Disease.” The Journal of Clinical Investigation. 117.8 (2007): 2302-2312.
Zajonc, Dirk M., et al. “Structural Basis for CD1d Presentation of a Sulfatide Derived from Myelin and Its Implications for Autoimmunity.” The Journal of Experimental Medicine. 202.11 (2005): 1517-1526.
Abreu, Sergio L. “Suppression of Experimental Allergic Encephalomyelitis by Interferon.” Immunological Communications. 11.1 (1982): 1-7.
Bolton, C. “The Translation of Drug Efficacy from In Vivo Models to Human Disease with Special Reference to Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.” Inflammopharmacology 15 (2007): 183-187.
Lublin, Fred D. “Relapsing Experimental Allergic Encephalomyelitis: An Autoimmune Model of Multiple Sclerosis.” Springer Seminars in Immunopathology. 8 (1985): 197-208.
Yednock, Ted A., et al, “Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against a4bl Integrin.” Nature. 365 (1992): 63-66.
Gold, Ralf, et al. “Understanding Pathogenesis and Therapy of Multiple Sclerosis Via Animal Models: 70 Years of Merits and Culprits in Experimental Autoimmune Encephalomyelitis Research.” Brain. 129 (2006): 1953-1971.
Teitelbaum, Dvora, et al. “Immunomodulation of Experimental Autoimmune Encephalomyelitis by Oral Administration of Copolymer 1.” Proceedings of the National Academy of Sciences. 96 (1999): 3842-3847.
Brossay, Laurent and Mitchell Kronenberg. “Highly Conserved Antigen-Presenting Function of CD1d Molecules.” Immunogenetics. 50 (1999): 146-151.
Kashiwase, Koichi. “The CD1d Natural Killer T-cell Antigen Presentation Pathway is Highly Conserved Between Humans and Rhesus Macaques.” Immunogenetics. 54 (2003): 776-781.

Affiliated with

Also associated with

Rating

Sulfatides for treatment of autoimmune disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfatides for treatment of autoimmune disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfatides for treatment of autoimmune disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4283589